# BMN 110 US Expanded Access Program

> **NCT01858103** · — · APPROVED_FOR_MARKETING · sponsor: **BioMarin Pharmaceutical**

## Conditions studied

- Mucopolysaccharidosis IVA
- Morquio A Syndrome
- MPS IVA

## Interventions

- **DRUG:** BMN 110

## Key facts

- **NCT ID:** NCT01858103
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2014-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01858103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01858103, "BMN 110 US Expanded Access Program". Retrieved via AI Analytics 2026-06-21 from https://api.ai-analytics.org/clinical/NCT01858103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*